These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20944132)

  • 1. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer.
    Daniele A; Zito AF; Giannelli G; Divella R; Asselti M; Mazzocca A; Paradiso A; Quaranta M
    Anticancer Res; 2010 Sep; 30(9):3521-7. PubMed ID: 20944132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
    Sliwowska I; Kopczyński Z
    Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
    Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
    Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients.
    Heo DS; Choi H; Yeom MY; Song BJ; Oh SJ
    Oncol Rep; 2014 Apr; 31(4):1567-72. PubMed ID: 24481627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.
    Sullu Y; Demirag GG; Yildirim A; Karagoz F; Kandemir B
    Pathol Res Pract; 2011 Dec; 207(12):747-53. PubMed ID: 22030137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
    Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
    Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases.
    Nos C; Harding-MacKean C; Fréneaux P; Trie A; Falcou MC; Sastre-Garau X; Clough KB
    Br J Surg; 2003 Nov; 90(11):1354-60. PubMed ID: 14598414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer.
    Ajisaka H; Yonemura Y; Miwa K
    Hepatogastroenterology; 2004; 51(57):900-5. PubMed ID: 15143943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement.
    Barranger E; Coutant C; Flahault A; Delpech Y; Darai E; Uzan S
    Breast Cancer Res Treat; 2005 May; 91(2):113-9. PubMed ID: 15868438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
    Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
    Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Very slight chance of other metastases in axillary nodes of breast cancer patients with a small sentinel node metastasis without extranodal tumor growth].
    van der Loo EM; Hop WC; Tervoort MA; de Graaf PW
    Ned Tijdschr Geneeskd; 2004 May; 148(19):938-43. PubMed ID: 15160561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between lymph node metastasis and the expressions of E-cadherin, N-cadherin, and matrix metalloproteinase in breast carcinoma].
    Wang LH; Liu DY; Chen YJ; Hou L; Wang B; Mao LM; Lu S
    Ai Zheng; 2002 Sep; 21(9):965-9. PubMed ID: 12508543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of lymph node and tumor matrix metalloproteinase expression in the analysis of metastatic periampullary tumors.
    McKenna GJ; Meneghetti A; Chen YL; Mui AL; Ong C; Scudamore CH; McMaster WR; Owen DA; Chung SW
    J Surg Oncol; 2005 Jun; 90(4):239-46. PubMed ID: 15906368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
    Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
    Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases.
    Xie M; Sun Y; Li Y
    Laryngoscope; 2004 Dec; 114(12):2243-8. PubMed ID: 15564854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma.
    Patel BP; Shah PM; Rawal UM; Desai AA; Shah SV; Rawal RM; Patel PS
    J Surg Oncol; 2005 May; 90(2):81-8. PubMed ID: 15844188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.